TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02663999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diazepam nasal spray
Description: diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diazepam nasal spray
Description: diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
Study: NCT01421524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are \> 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: Up to 10 subjects with relapsed or refractory PCNSL will be enrolled to a PCNSL cohort to evaluate intermittent schedules of CC-122 and to further explore preliminary signals of efficacy and biomarker hypotheses.
Study: NCT03270046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water enema
Description: Addition of water enema in standard PEG preparation in participants scheduled for CRC screening.
Study: NCT04402580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Biosimilar
Description: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
Study: NCT04138992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab will be used during neoadjuvant and concurrent chemoradiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDP
Description: DDP will be used during neoadjuvant and concurrent chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Description: DDP will be used during neoadjuvant and concurrent chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Description: DDP will be used during neoadjuvant and concurrent chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: used in neoadjuvant chemotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: standard treatment includes pelvic external beam radiation and brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: standard treatment includes pelvic external beam radiation and brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: standard treatment includes pelvic external beam radiation and brachytherapy
Study: NCT02483780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling
Description: The intervention will center on stories about living with hypertension, with patients speaking in their own words.
Study: NCT00973453

Intervention type: DRUG
Group type: OTHER
Intervention: PURETHAL Mites 20,000 AUeq/ml
Description: Group 1: slow regimen (12+2 injections) Initial treatment: incremental weekly dose of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.

Intervention type: DRUG
Group type: OTHER
Intervention: PURETHAL Mites 20,000 AUeq/ml
Description: Group 2: intermediate regimen (9+2 injections) Initial treatment: incremental weekly dose of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
Study: NCT04402580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 1,200 mg/1,73 sqm orally divided in 2 daily doses
Study: NCT02359409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: goggle balloon
Description: Colonoscopy will be performed using the water immersion technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water immersion only
Description: Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
Study: NCT00973453

Intervention type: DRUG
Group type: OTHER
Intervention: PURETHAL Mites 20,000 AUeq/ml
Description: Group 3: fast initial treatment (6+2 injections) Initial treatment: incremental weekly dose of 0.2, 0.4, 0.8, 1.2\*, 1.6\* and 2.0\*ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
Study: NCT01055561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Participators will be stimulated at specific acupuncture points as determined for the disease by the professional acupuncturists, and acupuncture once a day,last for one week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Participators will be stimulated at specific acupuncture points as determined for the disease by the professional acupuncturists, and acupuncture once a day,last for one week.
Study: NCT00934544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets packaged as 60-count in high-density polyethylene bottles
Study: NCT01594320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1)
Description: Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1)
Description: Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Description: Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Description: Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Description: Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Placebo; Intramuscular, deltoid, Day 0 \& Day 21
Study: NCT04441411

Intervention type: DEVICE
Group type: OTHER
Intervention: NEMOST system
Description: Minimal invasive double rod posterior Non-Fusion Scoliosis Surgery
Study: NCT03101566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360 mg or 240 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360 mg or 240 mg IV
Study: NCT02314325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVATE [Antihemophilic Factor (Recombinant)]
Description: In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVATE [Antihemophilic Factor (Recombinant)]
Description: In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen
Study: NCT04648813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide monohydrate (Spiriva Respimat)
Description: administered daily, 2 inhalations/5mcg per dose for a total of 8 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: administered daily, 2 inhalations per dose for a total of 8 doses
Study: NCT01168349

Intervention type: DRUG
Intervention: epoetin beta [NeoRecormon]
Description: As prescribed by physician
Study: NCT04354376

Intervention type: DRUG
Intervention: Loop diuretics, thiazides, dihydropyridines
Description: Loop diuretics, thiazides, or dihydropyridines dispensing claim is used as the reference

Intervention type: DRUG
Intervention: Telmisartan
Description: Telmisartan dispensing claim is used as the exposure
Study: NCT01757106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: general anaesthesia with xenon 50-60% in oxygen (FiO2=0.4-0.5)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: general anesthesia with sevoflurane 1.4% in 50% oxygen/medical air
Study: NCT04171531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox® injection
Description: Botulinum toxin A will be prepared by dissolving 100 units of botulinum toxin A into 10 ml of injectable saline. Indigo carmine or methylene blue 0.1 ml will be added to each syringe of botulinum toxin A. The treating physician will inject a total of 10 ml of the Botox A® into approximately 15 to 20 different detrusor muscle sites under direct visualization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mid-urethral sling
Description: Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Mini-sling and single-incision sling will not be allowed due to potential risk for higher failure rate.
Study: NCT02081157

Intervention type: DEVICE
Intervention: GalaFlex Mesh
Study: NCT02577692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: breathing oxygen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: breathing oxygen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient
Description: breathing ambient air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient
Description: breathing ambient air
Study: NCT02364141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk restraint therapy
Description: Reaching training with trunk restraint by a harness that limited the trunk movements.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trunk unrestraint therapy
Description: Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks
Study: NCT04085276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001 240mg, i.v., q3w; Other name: Toripalimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, i.v., q3w;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
Study: NCT02068326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalization Based Treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment As Usual
Study: NCT04578951

Intervention type: DEVICE
Intervention: FHK® total knee prosthesis
Description: FHK® prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
Study: NCT04226508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The patients can choose between three modality of EX:~1. Autonomous supervised training : a personalized activity is proposed. People choosing this modality have a written material, in which all the exercise, the activity, the frequency, the duration, the intensity are specifically described and reported, to perform the training at home. A training diary and 7 meetings (face to face, or skype or other modality) are proposed for monitoring the intervention.~2. Personal training program: a personalized activity is proposed. Patients are followed individually in a gym contest by a qualified kinesiologist.~3. Group training program: the training is performed in a small group, supervised and monitored by a qualified kinesiologist. The instructor-user ratio is 1:4 - 1:8, depending on the functional conditions and the heterogeneity of the participants.
Study: NCT00741052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 12 hourly oral dose of ciprofloxacin for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 1 gm Azithromycin single dose
Study: NCT03242629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral chloral hydrate
Description: Chloral hydrate syrup was available in a concentration of 100 mg×ml-1.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enema chloral hydrate
Description: Chloral hydrate syrup was available in a concentration of 100 mg×ml-1 at our hospital.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by enema.
Study: NCT01749306

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ABH001
Description: ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks
Study: NCT00934544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: Prescribing and usage per respective package inserts
Study: NCT01749306

Intervention type: OTHER
Group type: OTHER
Intervention: Control wound treatment
Description: Control wound care with protocol-specified dressings every 4 weeks (±1 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks
Study: NCT01218516

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Farletuzumab
Description: Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.~Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.~Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL\^min \[AUC5-6\].

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL\^min \[AUC5-6\].

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m\^2 will be administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m\^2 will be administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered intravenously.
Study: NCT00696059

Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab (Humira)
Description: Adalimumab (Humira) 40 mg subcutaneously every other week
Study: NCT03653858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vercise GEVIA deep brain stimulation (DBS) system
Description: DBS to the superolateral branch of the Medial Forebrain Bundle (slMFB)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vercise GEVIA deep brain stimulation (DBS) system
Description: DBS to the superolateral branch of the Medial Forebrain Bundle (slMFB)
Study: NCT03571204

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3BNC117 and 10-1074
Description: Both 3BNC117 and 10-1074 administered intravenously at 30 mg/kg dose level in 250 ml normal saline for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two antibodies will be mixed in separate bags of saline for sequential administration.
Study: NCT00508599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study 2 (48 hours of complete bed rest)
Description: Effects of 48 hours of bed rest on insulin resistance in type 2 diabetic subjects.
Study: NCT03904459

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention
Study: NCT02178033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Split dose low-volume PEG solution
Description: All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure.

Intervention type: DRUG
Group type: OTHER
Intervention: Split dose low-volume PEG solution
Description: All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure.
Study: NCT02643251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Hydrochloride Topical Gel, 0.1%
Description: Clonidine Gel is supplied as an aqueous gel formulation for topical use.
Study: NCT03571204

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3BNC117 and 10-1074
Description: Both 3BNC117 and 10-1074 administered intravenously at 30 mg/kg dose level in 250 ml normal saline for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two antibodies will be mixed in separate bags of saline for sequential administration.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is two separate bags of 250 ml normal saline administered intravenously for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two separate bags of placebo are administered sequentially.
Study: NCT04081779

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survivorship Care Plan
Description: Receive patient-generated SCP
Study: NCT02643251

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clonidine Hydrochloride Gel Comparator
Description: Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
Study: NCT04081779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan
Description: Receive patient-generated SCP
Study: NCT01726010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22-G Procore Needle
Study: NCT02264769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Study: NCT03989882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat germ energy ball
Description: wheat germ mixed other ingredients to make an energy ball

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: corresponding control without wheat germ